Hemp CBD manufacturer CV Sciences, Inc. CVSI has launched +PlusCBD Reserve Collection softgels to support stress relief and relaxation. This new CBD collection will be available online starting August 15th at $54.99 per 60-count bottle.
“It is important to the CV Sciences team that we create a range of options for consumers seeking to incorporate a microdose of CBD and THC into their daily lives,” Joseph Dowling, CEO of CV Sciences told Benzinga. “During times of anxiety, stress and depression, +PlusCBD Reserve Collection Softgels elicit powerful feelings of calm, comfort and relief in those needing support. The softgels are easy-to-take, convenient and carefully formulated to improve the quality of life of our consumers, demonstrating CV Sciences’ commitment to innovative, high-quality CBD and THC products."
+PlusCBD Reserve Highlights
+PlusCBD Reserve Collection softgels is the newest iteration of CV Sciences’ top-selling Reserve Collection, the brand’s sole THC line. Reserve Softgels are specially formulated to provide a full spectrum of cannabinoids, fostering feelings of calm and relief when consumers require intense support.
Reserve softgels feature a 10:1 ratio of CBD to THC (12.5mg CBD to 1.25mg THC), offering a manageable microdose perfect for consumers of all backgrounds and needs. These softgels are available in 60-count bottles.
The softgels are ideal for both men and women from Millenials to Boomers who are occasional CBD/THC users.
The Reserve softgels join the +PlusCBD Reserve Collection’s product lineup, featuring gummies and oils available in various flavors and potency.
“With the continued success of the Reserve Collection, an easy-to-take softgel is the perfect next addition to provide consumers with an even broader range of form factors,” Dowling stated. “CV Sciences consistently aims to offer consumers the highest-quality, most innovative ways to incorporate CBD and THC into their daily lives, actively targeting common issues like anxiety, depression and stress.”
Photo: Courtesy of CV Sciences
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis rescheduling seems to be right around the corner
Want to understand what this means for the future of the industry? Hear directly for top executives, investors and policymakers at the 19th Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. Get your tickets now before prices surge by following this link.